140 related articles for article (PubMed ID: 38271438)
1. A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice.
Woodcock IR; Tachas G; Desem N; Houweling PJ; Kean M; Emmanuel J; Kennedy R; Carroll K; de Valle K; Adams J; Lamandé SR; Coles C; Tiong C; Burton M; Villano D; Button P; Hogrel JY; Catling-Seyffer S; Ryan MM; Delatycki MB; Yiu EM
PLoS One; 2024; 19(1):e0294847. PubMed ID: 38271438
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial.
Clemens PR; Rao VK; Connolly AM; Harper AD; Mah JK; Smith EC; McDonald CM; Zaidman CM; Morgenroth LP; Osaki H; Satou Y; Yamashita T; Hoffman EP;
JAMA Neurol; 2020 Aug; 77(8):982-991. PubMed ID: 32453377
[TBL] [Abstract][Full Text] [Related]
3. Upper Limb Evaluation in Duchenne Muscular Dystrophy: Fat-Water Quantification by MRI, Muscle Force and Function Define Endpoints for Clinical Trials.
Ricotti V; Evans MR; Sinclair CD; Butler JW; Ridout DA; Hogrel JY; Emira A; Morrow JM; Reilly MM; Hanna MG; Janiczek RL; Matthews PM; Yousry TA; Muntoni F; Thornton JS
PLoS One; 2016; 11(9):e0162542. PubMed ID: 27649492
[TBL] [Abstract][Full Text] [Related]
4. Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study.
Ricotti V; Selby V; Ridout D; Domingos J; Decostre V; Mayhew A; Eagle M; Butler J; Guglieri M; Van der Holst M; Jansen M; Verschuuren JJGM; de Groot IJM; Niks EH; Servais L; Straub V; Voit T; Hogrel JY; Muntoni F
Neuromuscul Disord; 2019 Apr; 29(4):261-268. PubMed ID: 30852071
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical evaluation of N-acetylcysteine reveals side effects in the mdx mouse model of Duchenne muscular dystrophy.
Pinniger GJ; Terrill JR; Assan EB; Grounds MD; Arthur PG
J Physiol; 2017 Dec; 595(23):7093-7107. PubMed ID: 28887840
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
[TBL] [Abstract][Full Text] [Related]
8. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroids for the treatment of Duchenne muscular dystrophy.
Matthews E; Brassington R; Kuntzer T; Jichi F; Manzur AY
Cochrane Database Syst Rev; 2016 May; 2016(5):CD003725. PubMed ID: 27149418
[TBL] [Abstract][Full Text] [Related]
10. Electrical impedance myography detects dystrophin-related muscle changes in mdx mice.
Hiyoshi T; Zhao F; Baba R; Hirakawa T; Kuboki R; Suzuki K; Tomimatsu Y; O'Donnell P; Han S; Zach N; Nakashima M
Skelet Muscle; 2023 Nov; 13(1):19. PubMed ID: 37980539
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
[TBL] [Abstract][Full Text] [Related]
12. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy.
Chesshyre M; Ridout D; Hashimoto Y; Ookubo Y; Torelli S; Maresh K; Ricotti V; Abbott L; Gupta VA; Main M; Ferrari G; Kowala A; Lin YY; Tedesco FS; Scoto M; Baranello G; Manzur A; Aoki Y; Muntoni F
J Cachexia Sarcopenia Muscle; 2022 Apr; 13(2):1360-1372. PubMed ID: 35083887
[TBL] [Abstract][Full Text] [Related]
13. Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy.
Krishnan SM; Nordlohne J; Dietz L; Vakalopoulos A; Haning P; Hartmann E; Seifert R; Hüser J; Mathar I; Sandner P
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360780
[TBL] [Abstract][Full Text] [Related]
14. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.
Cirak S; Arechavala-Gomeza V; Guglieri M; Feng L; Torelli S; Anthony K; Abbs S; Garralda ME; Bourke J; Wells DJ; Dickson G; Wood MJ; Wilton SD; Straub V; Kole R; Shrewsbury SB; Sewry C; Morgan JE; Bushby K; Muntoni F
Lancet; 2011 Aug; 378(9791):595-605. PubMed ID: 21784508
[TBL] [Abstract][Full Text] [Related]
15. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial.
Mendell JR; Sahenk Z; Lehman K; Nease C; Lowes LP; Miller NF; Iammarino MA; Alfano LN; Nicholl A; Al-Zaidy S; Lewis S; Church K; Shell R; Cripe LH; Potter RA; Griffin DA; Pozsgai E; Dugar A; Hogan M; Rodino-Klapac LR
JAMA Neurol; 2020 Sep; 77(9):1122-1131. PubMed ID: 32539076
[TBL] [Abstract][Full Text] [Related]
17. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.
Limmroth V; Barkhof F; Desem N; Diamond MP; Tachas G;
Neurology; 2014 Nov; 83(20):1780-8. PubMed ID: 25239835
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study.
Goemans NM; Tulinius M; van den Hauwe M; Kroksmark AK; Buyse G; Wilson RJ; van Deutekom JC; de Kimpe SJ; Lourbakos A; Campion G
PLoS One; 2016; 11(9):e0161955. PubMed ID: 27588424
[TBL] [Abstract][Full Text] [Related]
19. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CM; Franco JV
Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013720. PubMed ID: 34850383
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
Manzur AY; Kuntzer T; Pike M; Swan A
Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
